Literature DB >> 22819074

Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells.

Masanobu Tsubaki1, Takao Satou, Tatsuki Itoh, Motohiro Imano, Makiko Komai, Minori Nishinobo, Megumi Yamashita, Masashi Yanae, Yuzuru Yamazoe, Shozo Nishida.   

Abstract

Multidrug resistance represents a major obstacle for the chemotherapy of a wide variety of human tumors. To investigate the underlying mechanisms associated with resistance to anti-cancer drugs, we established anti-cancer drug-resistant multiple myeloma (MM) cell lines RPMI8226/ADM, RPMI8226/VCR, RPMI8226/DEX, and RPMI8226/L-PAM, the 50% inhibitory concentration values of which were 77-, 58-, 79-, and 30-fold higher than their parental cell lines, respectively. The resistant cell lines overexpressed MDR1 and survivin, or showed decreased Bim expression. These results indicated that regulating these factors with inhibitors might be a viable approach to increasing the susceptibility of quiescent MM cells to chemotherapy.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22819074     DOI: 10.1016/j.leukres.2012.07.003

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  27 in total

1.  Reversal of multidrug resistance in gastric cancer cells by CDX2 downregulation.

Authors:  Lin-Hai Yan; Xiao-Tong Wang; Jie Yang; Chao Lian; Fan-Biao Kong; Wei-Yuan Wei; Wen Luo; Qiang Xiao; Yu-Bo Xie
Journal:  World J Gastroenterol       Date:  2013-07-14       Impact factor: 5.742

2.  Genetic polymorphisms and multiple myeloma risk: a meta-analysis.

Authors:  Pengcheng Zhang; Bing Liu
Journal:  Ann Hematol       Date:  2020-03-11       Impact factor: 3.673

3.  The FLT3 inhibitor midostaurin selectively resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.

Authors:  Sung-Han Hsiao; Sabrina Lusvarghi; Yang-Hui Huang; Suresh V Ambudkar; Sheng-Chieh Hsu; Chung-Pu Wu
Journal:  Cancer Lett       Date:  2019-01-11       Impact factor: 8.679

4.  Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines.

Authors:  Chung-Pu Wu; Ya-Ju Hsieh; Megumi Murakami; Shahrooz Vahedi; Sung-Han Hsiao; Ni Yeh; An-Wei Chou; Yan-Qing Li; Yu-Shan Wu; Jau-Song Yu; Suresh V Ambudkar
Journal:  Biochem Pharmacol       Date:  2018-07-17       Impact factor: 5.858

5.  Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression.

Authors:  Wen Zeng; Fankai Meng; Zeming Liu; Xia Mao; Li Luo; Miao Zheng; Shuang Qin; Wenli Liu; Jianfeng Zhou; Hanying Sun; Lifang Huang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

6.  Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.

Authors:  Chung-Pu Wu; Sabrina Lusvarghi; Jyun-Cheng Wang; Sung-Han Hsiao; Yang-Hui Huang; Tai-Ho Hung; Suresh V Ambudkar
Journal:  Mol Pharm       Date:  2019-06-04       Impact factor: 4.939

7.  SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines.

Authors:  Chung-Pu Wu; Megumi Murakami; Sung-Han Hsiao; Te-Chun Liu; Ni Yeh; Yan-Qing Li; Tai-Ho Hung; Yu-Shan Wu; Suresh V Ambudkar
Journal:  Cancer Lett       Date:  2018-07-06       Impact factor: 8.679

8.  Molecular chaperone gp96 is a novel therapeutic target of multiple myeloma.

Authors:  Yunpeng Hua; Shai White-Gilbertson; Joshua Kellner; Saleh Rachidi; Saad Z Usmani; Gabriela Chiosis; Ronald Depinho; Zihai Li; Bei Liu
Journal:  Clin Cancer Res       Date:  2013-09-27       Impact factor: 12.531

9.  The positive inotropic agent DPI-201106 selectively reverses ABCB1-mediated multidrug resistance in cancer cell lines.

Authors:  Sung-Han Hsiao; Megumi Murakami; Ni Yeh; Yan-Qing Li; Tai-Ho Hung; Yu-Shan Wu; Suresh V Ambudkar; Chung-Pu Wu
Journal:  Cancer Lett       Date:  2018-07-18       Impact factor: 8.679

10.  TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition.

Authors:  Prahlad V Raninga; Giovanna Di Trapani; Slavica Vuckovic; Kathryn F Tonissen
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.